Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) has a cash flow conversion efficiency ratio of 0.103x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥670.83 Million ≈ $98.16 Million USD) by net assets (CN¥6.50 Billion ≈ $950.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Shanghai Allist Pharmaceuticals Co. Ltd. to measure how many days the company can operate on defensive assets alone.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shanghai Allist Pharmaceuticals Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Allist Pharmaceuticals Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hancock Whitney Corp
NASDAQ:HWC
|
0.036x |
|
Bilibili Inc
NASDAQ:BILI
|
0.128x |
|
SmartSens Technology (Shanghai) Co. Ltd. A
SHG:688213
|
N/A |
|
WG Tech JiangXi Co Ltd
SHG:603773
|
0.041x |
|
MDA Ltd
TO:MDA
|
0.033x |
|
Caitong Securities Co Ltd
SHG:601108
|
-0.012x |
|
Ampol Ltd
AU:ALD
|
-0.021x |
|
Strathcona Resources Ltd.
TO:SCR
|
0.044x |
Annual Cash Flow Conversion Efficiency for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see 688578 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥14.40 Billion ≈ $2.11 Billion |
CN¥2.32 Billion ≈ $339.86 Million |
0.161x | -45.60% |
| 2024-12-31 | CN¥5.28 Billion ≈ $773.04 Million |
CN¥1.57 Billion ≈ $229.16 Million |
0.296x | +74.98% |
| 2023-12-31 | CN¥3.98 Billion ≈ $582.73 Million |
CN¥674.65 Million ≈ $98.72 Million |
0.169x | +489.25% |
| 2022-12-31 | CN¥3.19 Billion ≈ $466.37 Million |
CN¥91.63 Million ≈ $13.41 Million |
0.029x | +191.84% |
| 2021-12-31 | CN¥2.97 Billion ≈ $435.08 Million |
CN¥29.29 Million ≈ $4.29 Million |
0.010x | +114.41% |
| 2020-12-31 | CN¥2.88 Billion ≈ $421.15 Million |
CN¥-196.75 Million ≈ $-28.79 Million |
-0.068x | +68.78% |
| 2019-12-31 | CN¥1.18 Billion ≈ $173.31 Million |
CN¥-259.37 Million ≈ $-37.95 Million |
-0.219x | +84.00% |
| 2018-12-31 | CN¥71.04 Million ≈ $10.39 Million |
CN¥-97.25 Million ≈ $-14.23 Million |
-1.369x | -5261.91% |
| 2017-12-31 | CN¥381.26 Million ≈ $55.79 Million |
CN¥10.11 Million ≈ $1.48 Million |
0.027x | -- |
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl c… Read more